New York University has entered into an exclusive license with Proteostasis Therapeutics of Cambridge, MA, for IP related to discoveries from the laboratory of David Ron, MD, professor of medicine and Julius Raynes professor of cell biology at NYU Langone Medical Center’s Skirball Institute of Biomolecular Medicine. Ron’s research focuses on the unfolded protein response (UPR), and his laboratory identifies new components of the cellular response to stress — the mechanism behind many common diseases of aging. The UPR is an important part of the proteostasis network (PN), the cellular machinery that maintains protein health. The license accelerates the company’s drug discovery efforts to identify proteostasis regulators (PRs) — small molecule drugs designed to restore protein balance.
“Our lab is focused on uncovering new components of the cellular stress response and understanding their role in the pathology of human diseases,” says Ron, who has joined the company’s Scientific Advisory Board. “The UPR pathway is implicated in a broad range of diseases, including diabetes, Parkinson’s disease, inflammatory bowel disease, and retinal degeneration. Proteostasis Therapeutics’ novel drug discovery platform, which integrates multiple PN pathways, provides an advantage in rapidly developing UPR modulators identified by our lab into potential therapeutics for these diseases.”
Source: The Medical News